Careers  |  Media  |  Contact us

OncoLife – Targeted Colorectal panel – Extended (NGS)

Test Name

OncoLife – Targeted Colorectal panel – Extended (NGS)

Home Collection, Lab Visit

Test Code

ONCO0036

Test Components/ Genes/ Parameters

KRAS, NRAS, BRAF, MMR-IHC

Sample Report

Click on Icon

Test Information

TAT DETAILS

14 Days

PRE-TEST INSTRUCTIONS

Submit formalin fixed paraffin embedded Tissue Block. Ship at room temperature

CLINICAL UTILITY

The test detects mutations in KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4) and BRAF (codon 600 in exon 15) genes, all being part of the EGFR signaling cascade, are mutated in approximately 45–55% of the mCRC cases. Patients whose tumours have a mutated RAS gene are unlikely to respond to treatment with anti-epidermal growth factor receptor therapy such as cetuximab and panitumumab. MSI testing is used to classify CRC tumors as MSI-high (MSI-H), MSI-low, and microsatellite stable tumors. MSI-H or MMR deficient tumors have shown the best prognosis among all CRCs, so MSI testing is considered as a good prognostic marker.

SPECIMEN STABILITY

Transport at ambient (18-25°C) temperature

METHODOLOGY

NGS, IHC

STORAGE TEMPERATURE

NA

SPECIMEN TYPE

Surgical tissue/Tissue Block

Frequently Asked Questions

OncoLife – Targeted Colorectal panel – Extended (NGS)
It measures mutations in KRAS, NRAS and BRAF genes. MSI testing is considered as a good prognostic marker. it is also used to differentiate between sporadic and hereditary cancers.
The patient should carry the FFPE tissue or block of the Colon. This process is carried out by Gastero Surgeon in the hospital
If the patient is diagnosed with a Colon cancer and the doctor wants to determine whether the KRAS, NRAS& BRAF genes are mutated in the tumour. If the KRAS, NRAS & BRAF genes are mutated, the cancer will not be responsive to treatment with RAS targetted therapy
The test is performed by NGS technique
There is no risk associated with the test as biopsy will be taken by the trained surgeon in the hospital under anasthesia
The test report comes as mutated or wild type RAS or BRAF gene. Mutated RAS genes are unlikely to respond to treatment with anti-epidermal growth factor receptor therapy such as cetuximab and panitumumab. Patients with metastatic disease with wild-type (normal) RAS genes are likely to respond to these treatments, which improve the overall response to chemotherapy. MSI IHC will asess four specific MMR proteins resulting in a qualitative result of either a MSI high or MSI-stable phenotype and helps in making immunotherapy decisions for the patients.